Previous comparison studies of inpatient and outpatient forms of treatment for substance dependence have made direct comparisons of the outcomes and costs of these two forms of care under the assumption that both were designed to perform the same rehabilitation function. The present project proposes to compare two groups of 125 cocaine dependent patients randomly assigned to receive either Direct Admission to Intensive Outpatient treatment or to Brief (6-day) Inpatient Stabilization prior to Day Hospital rehabilitation. This study is unlike prior cost effectiveness comparisons because it specifically assumes that inpatient and outpatient treatments should not be evaluated on common outcome criteria. Instead, the study assumes that the appropriate function of inpatient care is to remove the barriers to and prepare the patient for outpatient care. Thus, the outcomes to be compared between the two groups include, engagement, retention and performance in Intensive Outpatient care, post-treatment outcomes as well as the total costs of each type of care. Patients will be evaluated at the start of the study, throughout the course of inpatient and Intensive Outpatient treatment and at six-month follow-up using validated instruments and procedures. All patient and treatment costs in both groups will be measured for comparative analyses. Specific hypotheses are that patients who receive brief stabilization first, will be more likely to engage in outpatient treatment, to complete that treatment and to have better outcomes at follow-up, than those randomly assigned directly to the Intensive Outpatient program. We believe the study is particularly pertinent to contemporary questions of cost, outcome and value in substance abuse treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Comprehensive Center (P60)
Project #
2P60DA005186-16
Application #
6544102
Study Section
Special Emphasis Panel (ZDA1)
Project Start
1992-09-30
Project End
2007-06-30
Budget Start
Budget End
Support Year
16
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Franklin, Teresa R; Jagannathan, Kanchana; Hager, Nathan et al. (2018) Brain substrates of early (4h) cigarette abstinence: Identification of treatment targets. Drug Alcohol Depend 182:78-85
Wetherill, Reagan R; Jagannathan, Kanchana; Hager, Nathan et al. (2016) Influence of menstrual cycle phase on resting-state functional connectivity in naturally cycling, cigarette-dependent women. Biol Sex Differ 7:24
Woody, George E; Krupitsky, Evgeny; Zvartau, Edwin (2016) Antagonist Models for Relapse Prevention and Reducing HIV Risk. J Neuroimmune Pharmacol 11:401-7
Van Horn, Deborah H A; Drapkin, Michelle; Lynch, Kevin G et al. (2015) Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatment. Addict Res Theory 23:391-403
Franklin, Teresa R; Jagannathan, Kanchana; Wetherill, Reagan R et al. (2015) Influence of menstrual cycle phase on neural and craving responses to appetitive smoking cues in naturally cycling females. Nicotine Tob Res 17:390-7
Kampman, Kyle M; Lynch, Kevin G; Pettinati, Helen M et al. (2015) A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend 155:105-10
Goldman, Marina; Ehrman, Ronald N; Suh, Jesse J et al. (2015) Brief report: ""spiders-No, puppies-Go"", introducing a novel Go NoGo task tested in inner city adolescents at risk for poor impulse control. J Adolesc 38:45-8
McKay, James R; Drapkin, Michelle L; Van Horn, Deborah H A et al. (2015) Effect of patient choice in an adaptive sequential randomization trial of treatment for alcohol and cocaine dependence. J Consult Clin Psychol 83:1021-32
Clarke, T-K; Crist, R C; Ang, A et al. (2014) Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females. Pharmacogenomics J 14:303-8
Clarke, Toni-Kim; Weiss, Amy R D; Ferarro, Thomas N et al. (2014) The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. Ann Hum Genet 78:33-9

Showing the most recent 10 out of 111 publications